Rapid detection of methicillin-resistant Staphylococcus aureus directly from clinical samples: methods, effectiveness and cost considerations.
Methicillin-resistant Staphylococcus aureus (MRSA) isolates is a serious public health problem whose ever-increasing rate is commensurate with the pressure it is exerting on the healthcare system. At present, more than 20% of clinical S. aureus isolates in German hospitals are methicillin resistant. Strategies from low-prevalence countries show that this development is not necessarily inevitable. In the Scandinavian countries and the Netherlands, thanks to a rigorous prevention programme, MRSA prevalence has been kept at an acceptably low level (<1-3%). Central to these 'search and destroy' control strategies is an admission screening using several MRSA swabs taken from mucocutaneous colonisation sites of high-risk patients ('MRSA surveillance').It has also been reported that the speed with which MRSA carriage is detected has an important role to play, as it is a key component of any effective strategy to prevent the pathogen from spreading. Since MRSA culturing involves a 2-3 day delay before the final results are available, rapid detection techniques (commonly referred to as 'MRSA rapid tests') using PCR methods and, most recently, rapid culturing methods have been developed. The implementation of rapid tests reduces the time of detection of MRSA carriers from 48-72 to 2-5 h. Clinical evaluation data have shown that MRSA can thus be detected with very high sensitivity. Specificity however is sometimes impaired due to false-positive PCR signals occurring in mixed flora specimens. In order to rule out any false-positive PCR results, a culture screen must always be carried out simultaneously. The data provide preliminary evidence that a PCR assay can reduce nosocomial MRSA transmission in high-risk patients or high-risk areas, whereas an approach that screens all patients admitted to the hospital is probably not effective. Information concerning the cost-effectiveness of rapid MRSA tests is still sparse and thus the issue remains debated.
Stürenburg
Enno
E
LADR GmbH, MVZ Dr. Kramer & Colleagues, Geesthacht, Germany. stuerenburg@ladr.de
D003362:Cost-Benefit Analysis; D004269:DNA, Bacterial / Q000032:analysis*; D006801:Humans; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000235:genetics / Q000302:isolation & purification*; D008826:Microbial Sensitivity Tests / Q000191:economics / Q000379:methods*; D016133:Polymerase Chain Reaction / Q000191:economics / Q000379:methods*; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000382:microbiology*
D004269:DNA, Bacterial
J Hosp Infect. 2004 Apr;56(4):321-5
15066745
Am J Infect Control. 2006 Oct;34(8):476-83
17015152
J Antimicrob Chemother. 2000 Oct;46(4):617-20
11020261
BMJ. 2008 Apr 26;336(7650):927-30
18417521
Clin Infect Dis. 1998 Sep;27(3):543-50
9770155
Infect Control Hosp Epidemiol. 2005 Feb;26(2):166-74
15756888
J Clin Microbiol. 2006 Jan;44(1):229-31
16390977
J Antimicrob Chemother. 2004 Jul;54(1):229-31
15150163
Clin Microbiol Infect. 2005 Jun;11(6):457-65
15882195
J Clin Microbiol. 2008 Jan;46(1):350-1
18032616
Infect Control Hosp Epidemiol. 1999 Jul;20(7):473-7
10432159
Clin Infect Dis. 2003 Jan 1;36(1):53-9
12491202
J Clin Microbiol. 2007 Jun;45(6):2011-3
17428926
J Clin Microbiol. 2007 Apr;45(4):1098-101
17287320
Infect Control Hosp Epidemiol. 2003 Jun;24(6):409-14
12828316
Ann Clin Microbiol Antimicrob. 2006 Feb 09;5:2
16469106
Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):782-6
12461587
J Clin Microbiol. 2008 Oct;46(10):3285-90
18685003
J Clin Microbiol. 2008 Jul;46(7):2151-4
18448693
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5620-5
16565219
J Clin Microbiol. 2004 May;42(5):1875-84
15131143
Infect Control Hosp Epidemiol. 2005 Jul;26(7):607-15
16092740
J Hosp Infect. 2002 Jul;51(3):189-200
12144798
Clin Microbiol Infect. 2006 Dec;12(12):1163-7
17121621
Clin Microbiol Infect. 2005 Oct;11(10):834-7
16153258
Infect Control Hosp Epidemiol. 2005 Feb;26(2):121-6
15756880
J Antimicrob Chemother. 2008 Jun;61(6):1277-80
18359757
J Clin Microbiol. 2006 Apr;44(4):1219-23
16597841
JAMA. 2008 Mar 12;299(10):1149-57
18334690
J Hosp Infect. 2008 Jun;69(2):124-30
18387695
Crit Care. 2006 Feb;10(1):R25
16469125
J Hosp Infect. 2007 Jan;65(1):24-8
17145100
Arch Intern Med. 2004 Oct 11;164(18):2038-43
15477440
Clin Microbiol Infect. 2005 Jun;11(6):466-71
15882196
Am J Epidemiol. 1996 Mar 1;143(5):496-504
8610665